Gene therapy for alpha-1 antitrypsin deficiency.

Abstract

Alpha-1 antitrypsin (AAT) deficiency is a common single-gene disorder among Northern Europeans and North Americans. The carrier frequency for the common missense mutation (Z-AAT) ranges from 4% in the US to nearly 25% in the Republic of Ireland. Severe AAT deficiency (plasma levels below 11 μm) is most commonly associated with an adult-onset lung disease, with pan-acinar emphysema and airway inflammation, which is thought to be primarily owing to the loss of function of AAT in neutralizing neutrophil elastase and other pro-inflammatory enzymes. In 5-10% of patients, severe liver disease may develop. This may occur at any time from infancy to adulthood, and is thought to be owing to toxicity from the Z-AAT mutant protein that folds poorly and forms insoluble polymers within the hepatocyte, which is the primary site for AAT production. Thus, gene therapy for AAT lung disease is conceived of as augmentation of serum levels (a prolonged form of protein replacement, which is currently in use), while gene therapy for liver disease presents the problem of also having to downregulate the production of Z-AAT protein. Over the years, numerous strategies have been employed for the gene therapy of both AAT-deficient lung disease and liver disease. These will be reviewed with an emphasis on modalities that have reached clinical trials recently.

• Authors: Terence R Flotte, Christian Mueller
• Journal: Human molecular genetics (Hum Mol Genet) Vol. 20 Issue R1 Pg. R87-92 (Apr 15 2011) ISSN: 1460-2083 [Electronic] England
• PMID: 21498872 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)

Topics

• Animals
• Genetic Therapy (methods)
• Hepatocytes (metabolism)
• Humans
• Liver Diseases (etiology)
• Lung Diseases (etiology)
• alpha 1-Antitrypsin Deficiency (complications, genetics, therapy)